Westlake Omics and AliveX Biotech Join Forces to Advance Multi-Omics Industry Empowerment

In February 2022, Westlake Omics signed a Memorandum of Cooperation with AliveX Biotech. By combining their respective strengths and starting from proteomics and metabolomics, and integrating AI + systems immunology analysis technology, the two parties will jointly advance the development of clinical multi-omics diagnostic products in the fields related to cancer and immune diseases. They will also provide pharmaceutical companies with new drug development services guided by biomarkers and targets, offering patients AI-powered precision diagnosis and treatment solutions.

In this collaboration, both parties will integrate their respective resources, technologies, and experiences to segment the beneficiary populations and develop novel biomarkers and therapeutic targets. By combining Westlake Omics' capabilities in proteomics and metabolomics data generation and analysis with AliveX Biotech's self-developed immune knowledge graph, multi-omics data integration and analysis, and AI mechanism modeling, the two sides will complement each other’s strengths to jointly address complex scientific challenges in research and development, significantly improving R&D efficiency and success rates.

He Dafeng, Vice President of Westlake Omics, stated: "AI + multi-omics is an important research field for life and health in the 21st century. As a leading AI + systems immunology company in China, AliveX Biotech’s collaboration with us will further deepen the multidimensional analysis of AI and multi-omics immune data based on proteomics, providing a more comprehensive understanding of the complex human system. Molecules are the essence of life activities, and multi-omics research represented by proteomics, metabolomics, and genomics is akin to the invention of a 'super microscope,' which will offer more precise solutions for early disease screening, diagnosis, prognosis, and drug development."

Ms. Wenwen Wen, Founder and CEO of AliveX Biotech, stated: "Dr. Tiannan Guo, founder of Westlake Omics, is an internationally renowned expert in proteomics. Westlake Omics possesses exceptional technical expertise in related fields, and we are highly honored to collaborate with them. Both companies have strong interdisciplinary technical teams. By joining forces to address the complex regulatory networks of the human body and clinical challenges, we can mutually benefit. Together, we will further advance the application of omics technologies in complex diseases, empowering more industry partners and promoting the development of new drug research and precision medicine, ultimately benefiting more patients."

About AliveX Biotech
AliveX Biotech has been committed to decoding human immunity using AI and multi-omics, understanding the essence of biology from the ground up, efficiently empowering the development of novel biomarkers and targets, and solving complex medical problems. The AliveX platform solution accelerates the discovery of biomarkers and targets and enhances the precision of therapeutic target screening through an innovative and efficient end-to-end technology platform, significantly improving R&D efficiency and success rates, and leading a new paradigm in next-generation life science research.

About Westlake Omics
Founded in July 2020, Westlake Omics is located in the Yunqi Town National Technology Park of Westlake University, Xihu District, Hangzhou City, Zhejiang Province. It is an innovative company focused on biotechnology breakthroughs and auxiliary clinical diagnostics. Addressing core issues related to life and health, Westlake Omics is committed to using technological innovation as its driving force and multimodal big data as its foundation. By leveraging AI to empower high-throughput proteomics analysis of trace clinical tissues and other omics technologies, the company supports precision medicine and drug development.

Editor: Baiji